Basiliximab Improves Graft Survival in Renal Transplant Recipients With Delayed Graft Function

Transplantation Proceedings

Volumn 39, Issue 2, 2007, Pages 437-438

  Goncalves L F ^a,b   Ribeiro, A R ^b   Berdichevski, R ^b   Joelsons, G ^b   Proenca M C ^b   Manfro, R C ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS;

ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DIALYSIS; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMORAL IMMUNITY; INCIDENCE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; BLOOD TRANSFUSION; CREATININE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES;

EID: 33847753883     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.01.041     Document Type: Article

References (8)

1. Sola R., Alarcon A., Jimenez C., et al. The influence of delayed graft function. Nephrol Dial Transplant 19 suppl 3 (2004) ii32
2. Tilney N.L., and Guttmann R.D. Effects of initial ischemia/reperfusion injury on the transplanted kidney. Transplantation 64 (1997) 945
3. Guttmann R.D. Delayed graft function, rejection, and long-term prognosis. Transplant Proc 32 (2000) 1453
4. Nashan B., Moore R., Amlot P., et al. Randomised trial of Basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 350 (1998) 1193
5. Vincenti F., Kirkman R., Light S., et al. Interleukin-2 receptor blockage with Daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338 (1998) 161
6. Boletis J.N., Theodoropoulou T., Hiras D., et al. Monoclonal antibody basiliximab with low cyclosporine dose as initial immunosuppression. Transplant Proc 33 (2001) 3184
7. Kuypers D.R.J., Evenpoel P., Maes B., et al. The use of anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant 17 (2003) 234
8. Jirasiritham S., Sumethkul V., Mavichak V., et al. The role of anti-IL2 receptor in high-risk kidney transplant patients. Transplant Proc 36 (2004) 2110